Bayer Can Still Take Hit If Litigation Strategy Fails -- Market Talk

Dow Jones

May 29

0741 GMT - Bayer's U.S. legal battles remain the main source of uncertainty looming over its shares, which could take a hit if the company's litigation strategy doesn't go to plan, Jefferies analysts say in a research note. The German agricultural-and-pharmaceutical conglomerate has captured a substantial majority of its litigation risk with an 11.8 billion-euro provision structure, according to Jefferies. That said, an adverse litigation outcome could prompt generalist investors to pivot out of Bayer, the analysts say. "Bayer may become significantly more investable, but this is not a given." Jefferies raises its target price on Bayer stock to 40 euros from 25 euros. Shares fall 0.8% to 37.55 euros. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 29, 2026 03:42 ET (07:42 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2639647100"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2639647100\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2639647100?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 15:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639647100","market":"sh","top_or_hot":-1,"title":"Bayer Can Still Take Hit If Litigation Strategy Fails -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0741 GMT - Bayer's U.S. legal battles remain the main source of uncertainty looming over its shares, which could take a hit if the company's litigation strategy doesn't go to plan, Jefferies analysts say in a research note. The German agricultural-and-pharmaceutical conglomerate has captured a substantial majority of its litigation risk with an 11.8 billion-euro provision structure, according to Jefferies. That said, an adverse litigation outcome could prompt generalist investors to pivot out of Bayer, the analysts say. \"Bayer may become significantly more investable, but this is not a given.\" Jefferies raises its target price on Bayer stock to 40 euros from 25 euros. Shares fall 0.8% to 37.55 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 03:42 ET (07:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer Can Still Take Hit If Litigation Strategy Fails -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer Can Still Take Hit If Litigation Strategy Fails -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-29 15:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0741 GMT - Bayer's U.S. legal battles remain the main source of uncertainty looming over its shares, which could take a hit if the company's litigation strategy doesn't go to plan, Jefferies analysts say in a research note. The German agricultural-and-pharmaceutical conglomerate has captured a substantial majority of its litigation risk with an 11.8 billion-euro provision structure, according to Jefferies. That said, an adverse litigation outcome could prompt generalist investors to pivot out of Bayer, the analysts say. \"Bayer may become significantly more investable, but this is not a given.\" Jefferies raises its target price on Bayer stock to 40 euros from 25 euros. Shares fall 0.8% to 37.55 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 03:42 ET (07:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2639647100","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639647100","pubTimestamp":1780040520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0741 GMT - Bayer's U.S. legal battles remain the main source of uncertainty looming over its shares, which could take a hit if the company's litigation strategy doesn't go to plan, Jefferies analysts say in a research note. The German agricultural-and-pharmaceutical conglomerate has captured a substantial majority of its litigation risk with an 11.8 billion-euro provision structure, according to Jefferies. That said, an adverse litigation outcome could prompt generalist investors to pivot out of Bayer, the analysts say. \"Bayer may become significantly more investable, but this is not a given.\" Jefferies raises its target price on Bayer stock to 40 euros from 25 euros. Shares fall 0.8% to 37.55 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BAYRY":"Bayer A.G."},"translate_title":"如果诉讼策略失败，拜耳仍可能遭受打击——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"0741 GMT - Bayer's U.S. legal battles remain the main source of uncertainty looming over its shares, which could take a hit if the company's litigation strategy doesn't go to plan, Jefferies analysts say in a research note. The German agricultural-and-pharmaceutical conglomerate has captured a substantial majority of its litigation risk with an 11.8 billion-euro provision structure, according to Jefferies. That said, an adverse litigation outcome could prompt generalist investors to pivot out of Bayer, the analysts say. \"Bayer may become significantly more investable, but this is not a given.\" Jefferies raises its target price on Bayer stock to 40 euros from 25 euros. Shares fall 0.8% to 37.55 euros. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2026 03:42 ET (07:42 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}